Close Menu

For the Rest

Johnson & Johnson bid 1.75 billion euros to buy the rest of the Dutch biotechnology company Crucell, reports The New York Times' DealBook, which notes that Johnson & Johnson already owns nearly 18 percent of the biotech. The offer for the company, which specializes in vaccines and therapeutics for infectious diseases, is 24.75 euros a share, and is supported by the Crucell board. The bid goes to a vote in early February.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.